News Headlines
-
Capricorn Scientific And Florabio Join Forces To Revolutionize Cell Culture Media In Biotech And Vaccine Industry With Animal-Free, High-Yield Solutions
4/16/2025
Capricorn Scientific GmbH, a leading provider of sterile cell culture media and animal-free powders for the biotech and diagnostics industries, proudly announces an innovative collaboration with florabio AS, led by the renowned biotechnologist Dr. Aziz Cayli, who brings over 30 years of expertise in the field.
-
Chime Biologics Partners Polpharma Biologics To Advance Global Biosimilar Development
4/16/2025
Chime Biologics, a leading global CDMO that enables its partners' success in biologics, is pleased to announce a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and manufacture of a biosimilar product for the global market.
-
Thermo Fisher Scientific Introduces The 5L DynaDrive Single-Use Bioreactor To Simplify And Accelerate Process Development And Help Bring Therapies To Market Faster
4/15/2025
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the 5L DynaDrive Single-Use Bioreactor (S.U.B.), designed to meet the evolving needs of modern bioprocessing.
-
Meribel Pharma Solutions Launches With Big Ambitions To Elevate Pharma Services To New Heights
4/15/2025
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions has launched today with an extensive integrated network across Europe, led by a team of industry experts on a mission to deliver the highest quality solutions and services to enable customers to scale to new heights and improve patient health.
-
Cyprumed Enters License And Option Agreement With MSD For The Development Of Oral Peptide Therapeutics
4/15/2025
Cyprumed GmbH, a dedicated drug delivery company specializing in innovative oral peptide formulations, and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced that the companies have signed a Non-Exclusive License and Option Agreement to develop oral formulations of MSD’s peptides using Cyprumed’s innovative drug delivery technology.
-
Lonza Joins Centre For Continuous Manufacturing And Advanced Crystallisation To Enhance Service Offering
4/14/2025
Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, today announced it has joined CMAC, a world leading centre for medicines manufacturing research, to enhance its service offering for particle technologies and drug product development and manufacture.
-
Applied StemCell Announces Drug Master File Submission To The US FDA For Their GMP-Grade iPSC Cell Line
4/14/2025
Applied StemCell, an advanced therapeutics CRO/CDMO specializing in iPSCs, gene editing, and small animal models, announced today that it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its ActiCells GMP Human Induced Pluripotent Stem Cell (hiPSC) line.
-
Boehringer Ingelheim And Cue Biopharma Partner To Develop Next-Generation Treatment For Autoimmune And Inflammatory Diseases
4/14/2025
Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases.
-
Next Expansion Milestone Achieved: SCHOTT Pharma Opens Production Facility In Serbia To Strengthen Competitiveness In Europe
4/10/2025
After breaking ground in December 2023, SCHOTT Pharma today inaugurated a new manufacturing facility in central Serbia.
-
Granules India Announces Closing Of Acquisition Of Senn Chemicals, Strengthening Capabilities In Peptide Therapeutics And CDMO Services
4/10/2025
Granules India Limited today announced the successful closing of the acquisition of Senn Chemicals AG, a Swissbased Contract Development and Manufacturing Organization (CDMO) specializing in peptide development and manufacturing.